What Prestalia Treats: Main Uses and Benefits

Prestalia is commonly used for the long-term management of high blood pressure (hypertension) in adult patients who may require combined symptomatic support. This includes its use in managing symptoms related to systemic imbalance.

The medication is relevant for easing symptoms related to systemic imbalance and organ-specific functional stress, applied across domains where short-term symptom management is appropriate. It is commonly used for managing symptoms of essential hypertension, including chronically elevated systolic and diastolic pressure readings. This therapeutic approach supports patients during difficult episodes by easing distress and is considered relevant for easing the overall symptom load.

This medication is applied in conditions presenting with systemic discomfort, particularly those characterized by periods of heightened symptoms associated with high blood pressure, and is used when managing symptoms linked to organ-specific functional stress. Delivering both agents in one tablet may assist with maintaining functional stability for the patient's daily routine.

---

Quick Fact: Support for Sustained Symptom Management This fixed-dose combination is relevant in clinical settings where patients require two approaches to help manage symptoms related to systemic imbalance, supporting the overall symptom load and contributing to general well-being.

Who can and cannot use Prestalia?

The official eligibility profile for Prestalia, a fixed-dose combination of amlodipine and perindopril, is defined strictly by regulatory authorities, outlining who may use the medicine and who is absolutely prohibited.

Populations for Whom Use is Contraindicated

Prestalia is Contraindicated in several specific populations, primarily due to the perindopril component (an ACE inhibitor):

• Pregnancy: Use in the second and third trimesters of pregnancy is prohibited due to the risk of fetal toxicity. Discontinuation is required immediately upon detection of pregnancy.
• Angioedema: Patients with a history of angioedema related to any prior ACE inhibitor or those with hereditary angioedema must not use the medicine.
• Drug-Drug Prohibitions: Concomitant use with medicine containing sacubitril/valsartan or the use of aliskiren in patients with Diabetes Mellitus is prohibited.
• Severe Conditions: Use is prohibited in patients with severe hypotension, cardiogenic shock, and high-grade aortic stenosis.

Restricted and Non-Established Use

• Age Groups: Safety and effectiveness have not been established in pediatric patients (under 18 years of age). Use in older adults may require specific dose consideration.
• Organ Function: The medicine is Not Recommended for patients with severe renal impairment (Creatinine Clearance less than 30 mL/min) or patients with hepatic impairment, as a dosage regimen is not established for these groups.

Interaction Map: Interactions with other medicines and products — official regulatory information for Prestalia

Interaction Scope

The regulatory profile for Prestalia formally documents interactions affecting both the perindopril and amlodipine components. Interacting medicine categories include Neprilysin Inhibitors, specific Dual Renin-Angiotensin-Aldosterone System (RAAS) agents, CYP3A4 modulators, and substances that significantly impact serum potassium levels. The officially described mechanisms involve pharmacokinetic alterations, such as enzyme inhibition leading to increased plasma concentration of amlodipine, and pharmacodynamic effects, which result in additive risks of excessive hypotension or elevated potassium.

---

Interaction Classifications (High-Level)

Regulatory documents establish certain combinations as contraindicated based on the severity of the interaction risk. Co-administration with Sacubitril/Valsartan is strictly prohibited, with a mandatory 36-hour separation window required when switching between therapies. The combination with Aliskiren is also contraindicated in patients who have diabetes mellitus or documented moderate-to-severe renal impairment. Other interaction-related constraints include a required maximum daily dose for Simvastatin (20 mg) to manage increased exposure resulting from co-administration.

---

Resulting Interaction Structure

Official statements specify risks with Potassium-Sparing Diuretics and Potassium Supplements due to the potential for developing hyperkalemia. The risk of angioedema is documented to be increased when co-administered with mTOR Inhibitors. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a reduction in the antihypertensive effect and increase the risk of renal impairment. The profile dictates strict avoidance of specific, high-risk combinations and the imposition of exposure limits for other co-administered products.

Prestalia combines two compounds, Perindopril and Amlodipine, which act via distinct mechanistic pathways on the cardiovascular system.

Perindopril: Angiotensin-Converting Enzyme Inhibition

Perindopril is an Angiotensin-Converting Enzyme (ACE) inhibitor that blocks the conversion of Angiotensin I to the vasoconstrictor Angiotensin II. This inhibition disrupts the Renin-Angiotensin-Aldosterone System (RAAS), leading to a decrease in peripheral vascular resistance via smooth muscle relaxation (vasodilation) and reduced aldosterone secretion.

Amlodipine: L-Type Calcium Channel Blockade

Amlodipine, a dihydropyridine calcium channel blocker, inhibits the influx of extracellular calcium ions into vascular smooth muscle and cardiac cells by binding to the L-type voltage-dependent calcium channels. This interaction reduces transmembrane calcium current, thereby decreasing vascular tone and peripheral resistance.

Dual Modulation

This combination utilizes complementary physiological pathways, modulating both the RAAS and calcium ion flux. This dual mechanism results in a sustained reduction of systemic peripheral vascular resistance and arterial pressure.

Prestalia is a fixed-dose combination (FDC) medicine administered exclusively through the oral route as a tablet, designed for use in a once-daily regimen. This administration schedule is established for long-term management and structures the intake process. The initial starting strength is 3.5 mg / 2.5 mg. The tablets may be taken with or without food, but consistent timing—ideally at the same time each day—is part of the procedural approach to ensure predictable systemic drug exposure.

The dose is not adjusted immediately but follows a structured titration schedule. Any decision to increase the strength must be separated by an interval of 7 to 14 days, which allows adequate time for the pharmacological effect to stabilize before proceeding to the next strength. The maximum recommended daily strength for adult patients is 14 mg / 10 mg.

Necessary restrictions are defined based on patient characteristics. For adult patients with moderate renal impairment (CrCL 30-80 mL/min), the dose is capped at 7 mg / 5 mg once daily. Conversely, the medication is not recommended for use in severe renal impairment (CrCL < 30 mL/min) or for pediatric patients under 18 years of age. If a dose is missed, the protocol is to take it as soon as possible, or to skip the dose if it is closer to the next scheduled administration time. This measured protocol defines the steps for the use of this FDC medicine.

Research evidence / Overview of studies for Prestalia

---

Research for Management of High Blood Pressure (Hypertension)

The clinical evaluation for Prestalia, a fixed-dose combination (FDC) of two approved blood pressure medicines, was primarily conducted through short-term Randomized Controlled Trials (RCTs). This type of research was used to explore what outcomes were observed in adult patients with essential high blood pressure, including those who were beginning treatment and those whose blood pressure was previously uncontrolled by a single medication. The evidence gathered in these trials was used to understand patterns related to outcomes such as the achievement of predefined blood pressure targets.

Trials compared the combination against the two components—amlodipine or perindopril—given alone. These studies explored whether taking the two agents together was associated with specific patterns in blood pressure measurements. Findings from these comparisons described that the combination was observed alongside greater measured changes to both Systolic and Diastolic Blood Pressure (SBP/DBP) measurements compared to those observed with either single agent. These outcomes monitored physiological strain related to blood pressure during the observed time intervals.

---

Studies on Durability and Intermediate-Term Effects

Research also examined the consistency of observed patterns over periods longer than the initial treatment phase. Studies were conducted for intermediate durations, sometimes extending up to twelve months, to monitor the consistency of measured blood pressure outcomes in the observed populations. These studies explored outcomes reflecting systemic or functional imbalance over defined time intervals.

Beyond the core blood pressure measurements, studies monitored biomarkers related to Target Organ Damage (TOD). This research examined outcomes linked to physiological strain on organs such as the heart and kidneys, including measurements of Left Ventricular Hypertrophy (LVH) (thickness of the heart muscle wall) and albuminuria (protein in the urine). Findings from these intermediate-term studies described the specific measurements recorded for these markers over the observation period, contributing to the broader evidence landscape.

---

Evidence in Specific Patient Groups

The medicine was evaluated in specific patient groups, particularly adults with concurrent heart conditions, such as Ischemic Heart Disease (IHD). Research examined outcomes related to physical discomfort and physiological strain in these individuals, and studies monitored the markers of target organ damage.

For older adults, the research provides context for use in this population. However, regulatory bodies have noted that there is limited information available specifically to guide dosing recommendations in patients older than 65 years. Data for certain groups, particularly those with specific comorbidities or advanced age, remain insufficient for definitive guidance.

---

Research Gaps and Uncertainties

The evidence base highlights what is known—and what is still uncertain—about the medicine. Although the combination was observed to result in lower blood pressure in the studies, a key limitation noted is the lack of controlled trials specifically dedicated to assessing the reduction in cardiovascular events (such as heart attack or stroke) directly for this fixed-dose combination product. The evidence for these critical long-term outcomes reflects the findings established by the individual components (ACE inhibitors and calcium channel blockers) in separate, independent research.

The clinical suitability has not been established in the pediatric population. These limitations mean that the results apply only to the adult populations studied and that long-term effects are not fully established by trials designed specifically for the FDC.

Key Studies & References

1. Clinical Review: Prestalia (amlodipine and perindopril) – NDA 205003
2. Prestalia (amlodipine and perindopril) Drug Information
3. Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review
4. The EPHES trial: effects of a fixed-dose combination of perindopril and amlodipine on markers of target organ damage in hypertension

Common questions about Prestalia (FAQ)

Q: Can Prestalia cause weight gain or loss?

A: Official regulatory documents acknowledge that both weight increase and weight decrease have been reported as uncommon or rare side effects in clinical data. These effects are documented and available in the full product information.

Q: Can Prestalia affect my sleep patterns?

A: Official product information indicates that the medication may affect sleep patterns. Both insomnia (difficulty sleeping) and somnolence (drowsiness or sleepiness) are listed among the uncommon adverse reactions documented in clinical studies.

Q: Does alcohol interact with Prestalia?

A: Official warnings state that alcohol may have additive effects in lowering blood pressure. This effect could increase the potential for symptoms such as dizziness, light-headedness, or fainting.

Q: Can men use Prestalia if they have erectile dysfunction concerns?

A: Regulatory documents list decreased libido (reduced sexual desire) and impotence (erectile dysfunction) as uncommon adverse reactions in clinical data. This information is available in the full prescribing documents.

Q: Can Prestalia be split in half if the tablet is scored?

A: While the official labeling describes the tablets as having specific markings, it does not explicitly state that the tablets are scored or can be safely split in half. Official information does not confirm that altering the tablet before taking it is appropriate.

Q: Are there generic versions of Prestalia available?

A: Studies and official information indicate that a generic version containing the two active ingredients, amlodipine and perindopril, is available in the marketplace. The specific original brand product's availability may vary by market and strength.

Q: Can I take cold and flu medication while on Prestalia?

A: Some over-the-counter cold and flu products contain ingredients like pseudoephedrine or phenylephrine, which can potentially counteract the blood pressure lowering effect of this medicine. Due to the risk of interaction, professional guidance is needed for any non-prescription medication.

Q: Does Prestalia cause changes in blood sugar?

A: Official regulatory documents list hyperglycemia (high blood sugar) as an uncommon adverse reaction observed in clinical data. This type of effect is noted in the adverse reaction section of the product information.

Q: Does Prestalia cause sun sensitivity or skin issues?

A: While official documents warn about a rare, severe swelling known as angioedema, other less serious skin reactions are also reported as uncommon. These reactions include general rash, pruritus (itching), and other forms of skin inflammation like urticaria (hives).

Q: Does Prestalia interact with grapefruit?

A: Grapefruit juice may cause a slight increase in the plasma concentration of the amlodipine component of the medicine. Regulatory sources generally note that the overall clinical significance of this interaction is minor.

Q: How often do I need to get blood tests while taking Prestalia?

A: Official labeling advises that monitoring for certain effects is necessary, particularly for kidney function and potassium levels. This is due to the risk of hyperkalemia (high potassium). Frequent blood tests may be needed during the course of treatment to check for unwanted effects.

Q: Can Prestalia interact with herbal supplements?

A: The official product label specifically documents a risk of interaction with potassium supplements. More broadly, regulatory information advises telling your doctor about all medications, vitamins, and herbs you take to allow for a full review of potential interactions.

Q: Does Prestalia interact with antacids or heartburn medication?

A: Regulatory information indicates that antacids may cause a minor decrease in the absorption of the perindopril component of the medication. The clinical significance of this interaction is generally considered minor and does not typically lead to a change in the drug's effectiveness.

Q: Does Prestalia have different effects based on race or ethnicity?

A: Clinical pharmacology data mentions that the ACE inhibitor component (perindopril) has shown a reduced average blood pressure response in Black patients compared to non-Black patients. This potential difference in response is noted in official documents.

Storage and Disposal of Prestalia

Prestalia (perindopril arginine and amlodipine) tablets must be stored and disposed of according to specific regulatory requirements to maintain their stability and efficacy.

Storage & Disposal Scope	Official Regulatory Requirement
Labeled Storage Temperature	Controlled room temperature (20 C to 25 C) (excursions: 15 C to 30 C).
Protection Requirements	Must be protected from moisture and heat.
Child-Protection Storage	Must be kept out of the sight and reach of children.
Disposal Instructions	Dispose of unused product and waste material in accordance with local regulatory requirements.

These conditions ensure the product is stored within the stable temperature and humidity range mandated by the FDA and other health authorities. For disposal, the regulatory instruction requires that expired or unused tablets be discarded following established local pharmaceutical waste procedures.